NuVasive, Inc. (NUVA) Tops Q2 EPS by 3c; Raises Outlook

NuVasive, Inc. (NASDAQ: NUVA) reported Q2 EPS of $0.28, $0.03 better than the analyst estimate of $0.25. Revenue for the quarter came in at $190.7 million versus the consensus estimate of $177.5 million.

NuVasive, Inc. sees FY2014 EPS of $1.11, versus prior guidance of $1.06 and the consensus of $1.09. NuVasive, Inc. sees FY2014 revenue of $745 million, versus prior guidance of $725 million and the consensus of $731 million.

We are pleased to report results that exceeded our expectations for both revenue and earnings and demonstrated strong progress toward our commitment to increase operational efficiency within NuVasive," said Alex Lukianov, Chairman and Chief Executive Officer of NuVasive. "Strength across our lumbar and biologics products in the U.S. and the continued healthy growth of our international geographies drove results for the quarter as we continued to solidly execute our share-taking strategy. Based on the greater than expected second quarter results and the strong momentum of our minimally invasive lumbar solutions, we are increasing our full year revenue, operating margin and earnings guidance for the year."

Lukianov continued, "I am exceptionally proud of our ability to maintain the nimbleness that has propelled NuVasive into the #3 spot in the global spine market. Our focus on championing innovation to improve patient outcomes while increasing profitability will continue to foster our evolution into a larger, more profitable, global organization."

For earnings history and earnings-related data on NuVasive, Inc. (NUVA) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Stantec (STN) Tops Q2 EPS by 47c
• Gaxos.ai Inc. (GXAI) Reports Q2 EPS of $0.02